Complex I Modulators Reduce Mitochondrial ROS Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective agents that can inhibit reactive oxygen species (ROS) formation mediated by mitochondrial Complex I, which is central to oxidative stress associated with various diseases.
Innovation Solution
Development of compounds that modulate the function of mitochondrial Complex I, specifically targeting the NADH-quinone oxidoreductase activity to reduce ROS generation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment of diseases is provided, but they fail to effectively inhibit ROS formation mediated by mitochondrial Complex I
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (formula I) that have optimized properties for targeting Complex I. The compounds feature specific substituents (R1-R6, R11-R15) and structural parameters that are tuned to achieve effective inhibition of Complex I-mediated ROS formation, transitioning from general therapies to targeted agents with controlled molecular characteristics.
2Object-generated harmful factors
If compounds modulating Complex I function are developed, then ROS generation is reduced, but therapeutic effectiveness for conditions associated with oxidative stress is achieved
Solution Approach 1:
The patent converts the harmful function of Complex I (which generates ROS as a byproduct of normal electron transport) into a beneficial target for therapy. By designing compounds that selectively modulate Complex I activity, the harmful ROS generation is reduced while maintaining the essential function of the enzyme, thereby converting a harmful physiological process into a controllable therapeutic target.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively treat or prevent conditions associated with Complex I-mediated oxidative stress, offering a therapeutic benefit by lowering ROS levels.
Implementation Method 1
One major source of ROS is oxidative phosphorylation via Complex I. The enzyme is a protein complex, encoded by 39 nuclear and 7 mitochondrial genes which is expressed ubiquitously and transfers electrons from NADH to Ubiquinone, coupled to translocation of protons necessary for ATP synthesis.
Implementation Method 2
The enzyme is a protein complex, encoded by 39 nuclear and 7 mitochondrial genes which is expressed ubiquitously and transfers electrons from NADH to Ubiquinone
Implementation Method 3
Oxidative stress reflects the imbalance between the generation and detoxification of Reactive Oxygen Species (ROS), which can cause toxic effects through the increased concentration of ROS, through disruption in cellular signaling and/or through damaging/oxidation of proteins, DNA or lipids.
Data Source
AI summary
The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I).